Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug;27(33):2200619.
doi: 10.2807/1560-7917.ES.2022.27.33.2200619.

Seroprevalence of antibodies against SARS-CoV-2 and risk of COVID-19 in Navarre, Spain, May to July 2022

Jesús Castilla  1   2   3 , Óscar Lecea  4 , Carmen Martín Salas  3   5 , Delia Quílez  6 , Ana Miqueleiz  3   5 , Camino Trobajo-Sanmartín  1   2   3 , Ana Navascués  3   5 , Iván Martínez-Baz  1   2   3 , Itziar Casado  1   2   3 , Cristina Burgui  1   2   3 , Nerea Egüés  1   2   3 , Guillermo Ezpeleta  1 , Carmen Ezpeleta  3   5
Affiliations

Seroprevalence of antibodies against SARS-CoV-2 and risk of COVID-19 in Navarre, Spain, May to July 2022

Jesús Castilla et al. Euro Surveill. 2022 Aug.

Abstract

In Navarre, Spain, in May 2022, the seroprevalence of anti-nucleocapsid (N) and anti-spike (S) antibodies of SARS-CoV-2 was 58.9% and 92.7%, respectively. The incidence of confirmed COVID-19 thereafter through July was lower in people with anti-N antibodies (adjusted odds ratio (aOR) = 0.08; 95% confidence interval (CI): 0.05-0.13) but not with anti-S antibodies (aOR = 1.06; 95% CI: 0.47-2.38). Hybrid immunity, including anti-N antibodies induced by natural exposure to SARS-CoV-2, seems essential in preventing Omicron COVID-19 cases.

Keywords: COVID-19 vaccine; Omicron variant; SARS-CoV-2; anti-N antibodies; natural immunity; sero-epidemiological survey.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared.

References

    1. Altarawneh HN, Chemaitelly H, Ayoub HH, Tang P, Hasan MR, Yassine HM, et al. Effects of previous infection and vaccination on symptomatic Omicron infections. N Engl J Med. 2022;387(1):21-34. . Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa2203965 10.1056/NEJMoa2203965 - DOI - DOI - PMC - PubMed
    1. World Health Organization (WHO). Interim statement on hybrid immunity and increasing population seroprevalence rates. Geneva: WHO; 1 Jun 2022. Available from: https://www.who.int/news/item/01-06-2022-interim-statement-on-hybrid-imm...
    1. Brandal LT, MacDonald E, Veneti L, Ravlo T, Lange H, Naseer U, et al. Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021. Euro Surveill. 2021;26(50):2101147. 10.2807/1560-7917.ES.2021.26.50.2101147 - DOI - PMC - PubMed
    1. Instituto de Salud Pública y Laboral de Navarra. Informe Epidemiológico Semanal 28/2022 (11 al 17 de julio de 2022). [Weekly epidemiological report 28/2022 (11–17 July 2022)]. Pamplona: Instituto de Salud Pública y Laboral de Navarra; 2022. Spanish. Available from: http://www.navarra.es/NR/rdonlyres/3855C06B-B6A2-4E05-BA57-034AB7947A04/...
    1. Centro de Coordinación de Alertas y Emergencias Sanitarias. Variantes de SARS-CoV-2 en España: linaje BA.2.12.1, BA.4 y BA.5 de Ómicron. [SARS-CoV-2 variants in Spain: Omicron lineages BA.2.12.1, BA.4 and BA.5]. Madrid: Ministerio de Sanidad; 2022. Spanish. Available from: https://www.sanidad.gob.es/profesionales/saludPublica/ccayes/alertasActu...